Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

StatusCompleted
PhasePhase 1
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Aug 26, 2026 to Aug 27, 2026
    • Eligibility criteria expanded, about 39 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 82 to confirmed 81
    • Primary and study completion dates: Aug 23, 2026 to Aug 26, 2026
    • Site details revised at 2 of 2 sites
    v4
  3. Site details revised at 1 of 2 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Primary and study completion dates: Aug 25, 2026 to Aug 23, 2026
    • Start date changed from estimate of Nov 18, 2025 to Oct 22, 2025
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
169 trials monitored
See 11 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Trial Details
NCT Number NCT07229157
Lead Sponsor Amgen
Conditions
(from sponsor)		 Overweight, Obesity
Related terms Obesity, Overweight
Enrollment 81 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov